Drug research has advanced in remarkable ways, but it’s still about the basics: ensuring safety, efficacy and compliance. That trio is no easy feat, but without a strong clinical strategy, even the most promising, safe and compliant drug can fail. Get your research in better strategic shape with this quick-start plan.
September 30, 2020
- Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
- Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
- The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
- Flow Cytometry User Groups And The Relaunch Of The NWFCS
- Live Dead Measurement and Cell Viability
Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know
The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...
Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...
The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
